UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.12.24

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.12.24 Share Price

DE000HC6HHS7

Market Closed - BOERSE MUENCHEN 01:12:25 15/06/2024 am IST
1.65 ^EUR	+5.10%

Current month	+48.65%
1 month	+153.85%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	14/06	MT
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress	14/06	BU
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing	14/06	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing	14/06	MT

More news

Quotes 5-day view

Date	Price	Change
14/24/14	1.65	+5.10%
13/24/13	1.57	+3.97%
12/24/12	1.51	-14.20%
11/24/11	1.76	-3.83%
10/24/10	1.83	-4.19%

Real-time BOERSE MUENCHEN

Last update June 15, 2024 at 01:12 am IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HC6HHS
ISIN	DE000HC6HHS7
Date issued	05/05/2023
Strike	550 $
Maturity	18/12/2024 (186 Days)
Parity	10 : 1
Emission price	1.92 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	2.54 €
Lowest since issue	0.45 €
Delta	0.32x
Omega	8.946
Premium	18.01x
Gearing	27.89x
Moneyness	0.8740
Difference Strike	69.27 $
Difference Strike %	+12.59%
Spread	0.04 €
Spread %	2.45%
Theoretical value	1.610
Implied Volatility	26.48 %
Total Loss Probability	74.38 %
Intrinsic value	0.000000
Present value	1.610
Break even	567.24 €
Theta	-0.07x
Vega	0.12x
Rho	0.07x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

480.7 USD

Average target price

463.4 USD

Spread / Average Target

-3.60%

Consensus